Abstract 1840P
Background
Diabetes mellitus is an important comorbidity to consider in cancer patients management because of its potentials multiples complications. Our objective was to evaluate the impact of diabetes mellitus in patient’s outcomes.
Methods
We performed a monocentric retrospective study. Patients treated for a first cycle of chemotherapy for cancer in Lille University Hospital Oncology Unit between May 2013 and May 2016 were included. Exclusion criteria were pts > 1 line of chemotherapy or with history of other cancer. A descriptive study was done.
Results
609 patients were included, 490 (80.5%) non diabetics and 119 (19.5%) diabetics. Tumour locations were digestive (106 pancreatic, 160 colorectal, 108 other), gynecological (136 breast, 55 ovarian, 20 uterus) and 18 primary unknown. Diabetics patients were older (median age at diagnosis [IQR]: 65.8 [59.9; 70.7] years in diabetics vs 59.9 [49.8; 67.4] years in non-diabetics), had more cardiac (57.6% vs 33.2%) and renal (15.1% vs 4.5%) comorbidities and had a higher BMI (median BMI: 30.3 [26.2; 34.5] kg / m2 in diabetics and 24.9 [22.2; 28.6] kg / m2 in non-diabetics). In the first 3 months of chemotherapy, grade 3/4 toxicities (G3/4 tox) occurred in 59 (49.6%) diabetics and 176 (35.9%) non diabetics patients. The most frequent G3/4 tox were infection and hematotoxicity, respectively 26% vs 19.5% and 13% vs 26.7% in diabetics and non-diabetics. Hospitalization during the first year of treatment occured in 60 (50.4%) diabetics and 160 (32.6 %) non diabetics patients. During first chemotherapy cycle, 45 (37.8%) diabetics patients had a cure delay versus 161 (32.9%) non diabetics and dose reduction was needed in 27 (22.7%) diabetics patients vs 122 (24.9%) non diabetics.
Conclusions
Diabetes mellitus is frequent in cancer patients with a severe impact in terms of grade 3/4 toxicities and hospitalization rate during chemotherapy. Updated and detailed data on diabetes related toxicity and impact in cancer management will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
CHU de Lille.
Funding
Has not received any funding.
Disclosure
C. Desauw: Travel/Accommodation/Expenses: Merck; Travel/Accommodation/Expenses: MSD; Travel/Accommodation/Expenses: Mundipharma. A. Turpin: Honoraria (self): Servier; Advisory/Consultancy, Travel/Accommodation/Expenses: Merck; Advisory/Consultancy: Amgen; Mylan; Travel/Accommodation/Expenses: Sanofi; Pfizer; AstraZeneca. All other authors have declared no conflicts of interest.